Richard Maisto
Founding Partner of Morpheus Capital
Richard Maisto is the Founding Partner of Morph Cap Advisors LLC, dba, Morpheus Capital Advisors. Morpheus is a boutique investment and merchant bank which most recently has focused on financing earlier stage companies that are bringing new technology to old industries. Morpheus provides financing, strategic, and CFO advice to its clients and is often an investor and board member.
Morpheus also provides advisory and financing services for later-stage companies, including debt and equity financings, M&A, debt restructurings, exclusive sales, and fairness opinions. Morpheus was founded in 2001 and has advised on billions of dollars worth of financings, debt restructurings, and M&A across many industries with concentrations in healthcare/biotech, transportation, real estate, energy, and general industrials.
Before founding Morpheus, Mr. Maisto was a Managing Director at Bankers Trust Alex Brown, where he covered private equity firms. He focused on developing acquisition opportunities, providing acquisition financing, and raising debt and equity financing for portfolio companies of private equity firms. He has spent most of his investment banking career providing advice to private equity firms and their portfolio companies, as well as advising on complex restructurings and bankruptcies.
Previously, Mr. Maisto was a Managing Director at Smith Barney, where he focused on both advising private equity firms and executing complex restructurings. Mr. Maisto began his career as a Vice President in Drexel Burnham’s restructuring group.
Mr. Maisto has served on numerous corporate boards and currently acts as a board member for Engineered Fluids, SURE Inc. and Accousys Biodevices Inc. Previously, he has been a member of Life Sciences Angels and a mentor to the Southern California Biomedical Council. He is a graduate of Columbia University (MBA) and Boston College (BS).
Thank you for taking the time to learn about Bexa
We’re working hard to continuously advance the sophistication of Bexa and to establish its role in the early detection of breast cancer.